Back to today’s briefing

Story perspectives

Apnimed's AD109 Shows 46.8% Drop in Sleep Apnea

7/24/2025

50 7

Summary

Story summary

Apnimed has unveiled promising results from the LunAIRo phase 3 trial of AD109, a groundbreaking once-daily oral treatment for obstructive sleep apnea. After 26 weeks, participants experienced a remarkable 46.8% drop in the Apnea-Hypopnea Index, alongside notable enhancements in oxygen levels. With this success, Apnimed aims to submit a New Drug Application to the FDA by early 2026.

1 of 1

Story summary

Apnimed has unveiled promising results from the LunAIRo phase 3 trial of AD109, a groundbreaking once-daily oral treatment for obstructive sleep apnea. After 26 weeks, participants experienced a remarkable 46.8% drop in the Apnea-Hypopnea Index, alongside notable enhancements in oxygen levels. With this success, Apnimed aims to submit a New Drug Application to the FDA by early 2026.